Skip to main content

"A Discussion on Genetic HypoPara"
Saturday, May15: 12:00pm - 1:30pm EST

Join us for our first informative and interactive workshop with expert doctors as we learn more about ADH1 and ADH2 as well as the new drug treatment, Encaleret, and what this means for the HypoPARA community

Knowledge and Insights You Don't Want to Miss from Expert Doctors!

ADH1 is a rare inherited genetic form of Hypoparathyroidism. The disease is caused by a mutation in the calcium sensing receptor (CaSR) resulting in abnormally low serum calcium and high urine calcium along with a range of debilitating symptoms including severe muscle cramping, tetany and seizures. In addition, relatively high levels of calcium in urine can often result in kidney stone formation and impaired kidney function.

In this live webinar Dr. RoszkoDr. Hartley and Dr. Gafni will talk about the latest research being done for ADH1 and ADH2 hypoparathyroidism. Highlighted in this workshop will be the encouraging and remarkable successes being shown with Encaleret, a new drug treatment specifically developed for ADH1. Much history and details surrounding these topics will be shared and participants will be able to ask questions directly to the doctors.

Come as you are and learn from some of the top doctors in the field of hypoparathyroidism. This webinar marks the first of many to come from the HypoPARA Association. 

This webinar is being sponsored by Calcilytics, a BridgeBio company.


Click the button to register. Space is limited so do it now and mark your calendar!

This information is provided for educational purposes only. It should not be used for diagnostic or treatment purposes. If you wish to obtain more information about this disorder, please contact your personal physician.